Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Verve To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Verve between August 9, 2022 and April 1, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983- 9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Aug. 29, 2024 (GLOBE NEWSWIRE ...

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Verve Therapeutics, Inc. ("Verve" or the "Company") (NASDAQ: VERV) in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Verve securities between August 9, 2022, and April 1, 2024, both dates inclusive (the "Class Period"). Investors h ...

NEW YORK, Aug. 28, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August 9, 2022 and April 1, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 28, 2024 in the securities class action first filed by the Firm. So wha ...

SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Verve Therapeutics, Inc. (NASDAQ: VERV) securities between August 9, 2022 and April 1, 2024. Verve is a "clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines." For more information, ...

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Verve Therapeutics, Inc. ("Verve Therapeutics" or "the Company") (NASDAQ: VERV) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise a ...

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who purchased or otherwise acquired Verve Therapeutics, Inc. ("Verve" or the "Company") (NASDAQ: VERV) securities between August 9, 2022 and April 1, 2024, inclusive (the "Class Period"). The lawsuit seeks to recover damages for the Company's investors under the federal ...

ATLANTA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Verve Therapeutics, Inc. ("Verve Therapeutics" or "the Company") (NASDAQ: VERV). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company's business, operations, and prospects, including allegations that: (1) Defendants did not fully disclose the circumstances under which the Heart-1 trial would be halted; and (2 ...

NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Verve Therapeutics, Inc. (NASDAQ: VERV) between August 9, 2022 and April 1, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than October 28, 2024 in the securities class action first filed by the Firm. SO ...

NEW YORK, Aug. 8, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Verve Therapeutics, Inc. (NASDAQ: VERV) on behalf of the company's shareholders. The investigation seeks to determine whether Verve Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions. If you are a shareholder of Verve Therapeutics, Inc. and are interested in obtaining additional information regarding your rights and options, free of charge, please visit us at: h ...

Verve Therapeutics (VERV) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.87 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 13.24%. A quarter ago, it was expected that this biotechnology firm would post a loss of $0.68 per share when it actually produced a loss of $0.59, delivering a surprise of 13.24%. Over the last four quarters, the comp ...